IP Library Granted Patent US 10,912,863
Granted Patent B2
US 10,912,863 · App. 16/169,180 · Granted Feb 9, 2021

Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase

Inventors: David Ayares (Blacksburg, VA); Paul Rohricht (Mertztown, PA)
Assignee: Revivicor, Inc.
A61L27/3683A01K67/0276A61L27/3604A61L27/3629A61L27/3641A61L27/3695C12N9/1051C12N15/8509A01K2217/075A01K2227/108A01K2267/02A01K2267/025A61K35/12A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,912,863
App. No.
16/169,180
Granted
Feb 9, 2021
Kind
B2
Abstract

The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.

Claims (12)

1. A tissue product, comprising a tissue stripped of viable cells, wherein the tissue is derived from an internal tissue of a porcine animal in which at least one allele of an α-1,3-galactosyltransferase gene is inactivated and wherein the animal lacks expression of α-1,3-galactosyltransferase, wherein the internal tissue is selected from the group consisting of heart valves, pericardial tissue and blood vessels.

2. The internal tissue product of claim 1 , wherein the internal tissue stripped of viable cells is produced by enzymatic treatment.

3. The internal tissue product of claim 1 , wherein the internal tissue stripped of viable cells is produced by chemical treatment.

4. The internal tissue product of claim 2 , wherein the internal tissue can be further processed via crosslinking treatments.

5. The internal tissue product of claim 2 , wherein the internal tissue can be further processed via additional chemical treatments.

6. The internal tissue product of claim 1 , wherein at least one allele of the alpha-1,3-GT gene is inactivated by a genetic targeting event.

7. The internal tissue product of claim 6 , wherein both alleles of the alpha-1,3-GT gene are inactivated by genetic targeting events.

8. The internal tissue product of claim 1 , wherein the heart valve is selected from the group consisting of a tricuspid valve, pulmonary valve, mitral valve, and an aortic valve.

9. The internal tissue product of claim 1 , wherein the heart valve is selected from the group consisting of the: mitral valve, atrial valve, aortic valve, tricuspid valve, pulmonary valve, plumonic patch, descending thoracic aorta, aortic non-valve conduit, pulmonic non-valve conduit with the left and right pulmonary artery, right or left pulmonary hemi-artery with intact cusp, right or left pulmonary hemi-artery without intact cusp, saphenous vein, aortoiliac, femoral vein, femoral artery and semi-lunar valve.

10. The internal tissue product of claim 1 , wherein the internal tissue is a blood vessel and the tissue product is suitable for use as a vascular graft.

11. The internal tissue product of claim 1 , wherein the blood vessel is the carotid artery.

12. The internal tissue product of claim 1 , wherein the internal tissue is pericardial tissue and the tissue product is suitable for use as a patch during surgical procedures.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: AYARES, DAVID; ROHRICHT, PAUL
To: REVIVICOR, INC.
Reel/Frame 048728/0686 →